The Daily Ozempic for All?
366 snips
Nov 14, 2025 
Eshe Nelson, an economics and business reporter for The New York Times based in London, dives into the transformation of GLP-1 drugs like Ozempic and Wegovy. She discusses the upcoming pricing changes that promise broader access, stemming from a significant agreement struck with pharmaceutical companies during the Trump administration. The conversation also covers how Ozempic evolved from a diabetes drug to a weight-loss sensation, and the ensuing supply challenges faced by its maker, Novo Nordisk, amid skyrocketing demand.
AI Snips
Chapters
Transcript
Episode notes
Access Is About To Expand Rapidly
- GLP-1 drugs like Ozempic are entering a new phase as pill forms and policy changes expand access.
- Pills and broader coverage could dramatically increase the number of Americans using these drugs.
Prepare For Insurance Coverage Changes
- Expect Medicare and Medicaid coverage to change and prepare for wider eligibility starting next year.
- Check with your insurer and providers about coverage updates for GLP-1 drugs.
From Insulin Maker To Weight-Loss Pioneer
- Novo Nordisk pioneered GLP-1 diabetes drugs and iteratively improved them into powerful weight-loss treatments.
- Semaglutide (Ozempic) moved from daily to weekly dosing and produced far larger weight loss results.